GlassScriptPhysician profile
Wanda Casiano
NPI 1740356468
$8,693.65
in general payments reported to CMS, 2019-2025
37 companies · $1,759 in 2025
The $1,759 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,617 · 2020: $1,130 · 2021: $647 · 2022: $835 · 2023: $787 · 2024: $919 · 2025: $1,759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,443 · Education: $22.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,443.02 |
| Education | $22.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,303.24 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $1,169.11 | 2019-2025 | Opdivo, Reblozyl |
| Merck Sharp & Dohme LLC | $728.11 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Pbg Puerto Rico LLC | $688.32 | 2019-2025 | |
| Genentech USA, INC. | $598.81 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Novartis Pharmaceuticals Corporation | $596.21 | 2019-2025 | |
| Abbvie INC. | $583.43 | 2019-2025 | Venclexta |
| Janssen Pharmaceuticals, INC | $512.02 | 2019-2025 | Darzalex, Rybrevant, Erleada |
| Tempus Ai, INC | $329.95 | 2024-2025 | Xt Cdx |
| Amgen INC. | $303.42 | 2019-2024 | Xgeva, Vectibix, Lumakras |
| Eli Lilly Export S.A. Puerto Rico Branch | $302.55 | 2019-2020 | |
| Genzyme Corporation | $175.97 | 2019-2025 | |
| Glaxosmithkline, LLC. | $169.90 | 2020-2024 | Zejula, Jemperli, Ojjaara |
| Bayer Puerto Rico INC. | $149.83 | 2024-2025 | Nubeqa, Stivarga |
| Taiho Oncology, INC. | $130.21 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $125.21 | 2024-2025 | Libtayo, Lynozyfic |
| Pfizer Pharmaceuticals LLC | $105.71 | 2019 | |
| Puma Biotechnology, INC. | $102.59 | 2019-2025 | |
| Celgene Corporation | $83.43 | 2019 | |
| Pfizer INC. | $53.12 | 2019-2025 | |
| Sobi, INC | $42.78 | 2025 | |
| Caris Mpi, INC. | $42.70 | 2025 | Mi Cancer Seek |
| Clovis Oncology, INC. | $42.26 | 2020 | |
| Springworks Therapeutics, INC. | $39.59 | 2025 | Ogsiveo |
| Eisai INC. | $38.42 | 2019-2020 | |
| Zimmer Biomet Holdings, INC. | $34.00 | 2019 | |
| Lilly USA, LLC | $32.46 | 2020 | |
| Gilead Sciences, INC. | $24.34 | 2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $22.96 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Ipsen Biopharmaceuticals, INC | $22.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.22 | 2019 | |
| Seagen INC. | $21.83 | 2021 | |
| Incyte Corporation | $20.13 | 2025 | Monjuvi, Zynyz, Jakafi |
| Tolmar, INC. | $19.47 | 2025 | Rubraca |
| Pharmaand Gmbh | $19.47 | 2025 | Rubraca |
| Shire North American Group INC | $19.17 | 2019 | |
| Astellas Pharma US INC | $18.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Casiano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.